Pilot study of cardiac function after treatment of childhood Wilms' tumor with doxorubicin.

Abstract

To assess the cardiotoxicity of moderate doses of anthracyclines and to control for possible contributions of other drugs, cardiac function in 12 patients 1 year 11 months to 9 years 4 months off treatment for Wilms' tumor whose therapy had included vincristine, dactinomycin, and the anthracycline doxorubicin (270 to 300 mg/m2 cumulative dose) was compared with that of 9 patients (controls) whose therapy had included vincristine and dactinomycin but not doxorubicin. The small numbers of patients studied suggest that a a medium of 6 years off therapy only small numbers of patients will have cardiac function values below age-related normal values. To confirm these results and to determine whether abnormalities are progressive or are clinically important, large cohorts of patients such as those available to the National Wilms' Tumor Study need to be studied.

• Authors: J Blatt, C DeLaat, F J Fricker, J E Janosky
• Journal: Pediatric hematology and oncology (Pediatr Hematol Oncol) 1995 Jan-Feb Vol. 12 Issue 1 Pg. 61-6 ISSN: 0888-0018 [Print] England
• PMID: 7703043 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Doxorubicin

Topics

• Child
• Child, Preschool
• Doxorubicin (adverse effects)
• Electrocardiography
• Heart (drug effects)
• Humans
• Infant
• Kidney Neoplasms (drug therapy)
• Pilot Projects
• Ventricular Function, Left (drug effects)
• Wilms Tumor (drug therapy)